Market Cap 2.29B
Revenue (ttm) 2.11B
Net Income (ttm) 169.00M
EPS (ttm) N/A
PE Ratio 12.14
Forward PE 12.93
Profit Margin 8.00%
Debt to Equity Ratio 0.54
Volume 690,300
Avg Vol 596,676
Day's Range N/A - N/A
Shares Out 45.70M
Stochastic %K 45%
Beta 0.52
Analysts Strong Sell
Price Target $68.11

Company Profile

Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; and nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives. Its Pe...

Industry: Specialty Chemicals
Sector: Basic Materials
Phone: 302 995 3000
Address:
8145 Blazer Drive, Wilmington, United States
ZacksResearch
ZacksResearch May. 6 at 1:35 PM
$ASH misses big — but is the pain temporary or structural? Q2 earnings and revenues both missed estimates and declined year over year, as portfolio optimization actions weighed on sales. Full breakdown here 👉 https://www.zacks.com/stock/news/2463062/ashlands-q2-earnings-and-revenues-miss-estimates-down-yy?cid=sm-stocktwits-2-2463062-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2463062_TEASER
0 · Reply
Estimize
Estimize Apr. 30 at 8:00 PM
Wall St is expecting 1.47 EPS for $ASH Q3 [Reporting 07/29 AMC] http://www.estimize.com/intro/ash?chart=historical&metric_name=eps&utm_cont
0 · Reply
Bsheskey
Bsheskey Apr. 15 at 8:16 PM
$ASH Could Quickly Scale into GLP-1 API's if Pharma Tariffs take effect. $NVO or $LLY should target. ASAP
0 · Reply
JarvisFlow
JarvisFlow Apr. 9 at 5:30 PM
Wells Fargo updates rating for Ashland ( $ASH ) to Overweight, target set at 69 → 58.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 10:26 AM
$ASH Digging ASH's strategic pivot. Avoca sale looks smart. Life Sciences hit hard but Personal Care segment showing resilience. Watching how cost-cutting plays out. Cautiously optimistic on long-term potential. Might nibble on dip if market overreacts. compelling writeup: https://beyondspx.com/article/ashland-inc-ash-a-specialty-chemicals-powerhouse-navigating-challenges-with-strategic-precision
0 · Reply
IndulgeJackal
IndulgeJackal Mar. 27 at 1:52 PM
$ASH 🚨 BREAKING NEWS from Mainz Biomed 🚨 Mainz Biomed just enrolled the first patient in its eAArly DETECT 2 clinical study - a groundbreaking 2,000-patient trial designed to validate its next-gen colorectal cancer (CRC) test that could shift CRC screening to prevention! 🧬🔍 Key Highlights: ✅ Industry-leading mRNA biomarkers + AI-driven algorithm ✅ Detects advanced precancerous lesions (APL) with high precision ✅ Potential to prevent CRC by catching treatable polyps early ✅ Top-line results expected Q4 2025 ✅ Pivotal U.S. study (ReconAAsense) planned for 2026 “This marks a huge milestone in our mission to eliminate colorectal cancer and save lives,” said CEO Guido Baechler. 🌍💥
0 · Reply
JarvisFlow
JarvisFlow Mar. 27 at 1:04 PM
Wells Fargo has adjusted their stance on Ashland ( $ASH ), setting the rating to Overweight with a target price of 80 → 69.
0 · Reply
JarvisFlow
JarvisFlow Mar. 26 at 12:00 PM
JP Morgan updates rating for Ashland ( $ASH ) to Overweight, target set at 68 → 71.
0 · Reply
ajmrtxl
ajmrtxl Mar. 25 at 5:09 PM
$ASH's latest data on SqueezeFinder
0 · Reply
BigSqueezeComing
BigSqueezeComing Mar. 24 at 11:04 AM
$DMN $ASH $IMTE $WINT $MLGO continue from AH
0 · Reply
Latest News on ASH
Ashland hosts Innovation Day for analysts and investors

May 28, 2025, 5:00 PM EDT - 27 days ago

Ashland hosts Innovation Day for analysts and investors


Ashland board authorizes quarterly dividend

May 6, 2025, 5:15 PM EDT - 7 weeks ago

Ashland board authorizes quarterly dividend


Ashland announces executive leadership changes

May 5, 2025, 5:00 PM EDT - 7 weeks ago

Ashland announces executive leadership changes


Ashland, Inc. (ASH) Q2 2025 Earnings Call Transcript

May 1, 2025, 7:48 PM EDT - 7 weeks ago

Ashland, Inc. (ASH) Q2 2025 Earnings Call Transcript


Ashland to host 2025 Innovation Day for analysts and investors

Mar 28, 2025, 6:59 AM EDT - 3 months ago

Ashland to host 2025 Innovation Day for analysts and investors


Ashland completes sale of Avoca business to Mane

Mar 17, 2025, 7:00 AM EDT - 3 months ago

Ashland completes sale of Avoca business to Mane


Ashland Presents Attractive Upside Emerging From The Downcycle

Feb 27, 2025, 2:14 PM EST - 4 months ago

Ashland Presents Attractive Upside Emerging From The Downcycle


The Best Materials Stocks to Buy

Feb 10, 2025, 12:53 PM EST - 4 months ago

The Best Materials Stocks to Buy

AVY BALL DD FMC GPK PKG RPM


Ashland Inc. (ASH) Q1 2025 Earnings Call Transcript

Jan 29, 2025, 9:24 PM EST - 5 months ago

Ashland Inc. (ASH) Q1 2025 Earnings Call Transcript


Forget The S&P 500 - 3 Small Dividend Stocks At Big Discounts

Jan 23, 2025, 7:30 AM EST - 5 months ago

Forget The S&P 500 - 3 Small Dividend Stocks At Big Discounts

BNL SMG


Ashland Inc. (ASH) Q4 2024 Earnings Call Transcript

Nov 9, 2024, 4:16 PM EST - 8 months ago

Ashland Inc. (ASH) Q4 2024 Earnings Call Transcript


Top 3 Materials Stocks That Are Preparing To Pump In Q4

Nov 8, 2024, 9:09 AM EST - 8 months ago

Top 3 Materials Stocks That Are Preparing To Pump In Q4

CE MATV


Ashland completes sale of nutraceuticals business

Sep 3, 2024, 7:00 AM EDT - 10 months ago

Ashland completes sale of nutraceuticals business


Ashland Inc. (ASH) Q3 2024 Earnings Call Transcript

Aug 7, 2024, 6:27 PM EDT - 11 months ago

Ashland Inc. (ASH) Q3 2024 Earnings Call Transcript


Ashland achieves certification by Fair Wage Network

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Ashland achieves certification by Fair Wage Network


13 Upcoming Dividend Increases

May 27, 2024, 10:31 PM EDT - 1 year ago

13 Upcoming Dividend Increases

ACNB CBT DE EVR FDS HBB HY


Ashland Board appoints Ashish K. Kulkarni as new director

May 8, 2024, 5:01 PM EDT - 1 year ago

Ashland Board appoints Ashish K. Kulkarni as new director


Ashland Inc. (ASH) Q2 2024 Earnings Call Transcript

May 1, 2024, 4:04 PM EDT - 1 year ago

Ashland Inc. (ASH) Q2 2024 Earnings Call Transcript


Ashland Board appoints Scott A. Tozier as new director

Apr 15, 2024, 6:59 AM EDT - 1 year ago

Ashland Board appoints Scott A. Tozier as new director


Ashland Inc. (ASH) Q1 2024 Earnings Call Transcript

Jan 31, 2024, 4:34 PM EST - 1 year ago

Ashland Inc. (ASH) Q1 2024 Earnings Call Transcript


ZacksResearch
ZacksResearch May. 6 at 1:35 PM
$ASH misses big — but is the pain temporary or structural? Q2 earnings and revenues both missed estimates and declined year over year, as portfolio optimization actions weighed on sales. Full breakdown here 👉 https://www.zacks.com/stock/news/2463062/ashlands-q2-earnings-and-revenues-miss-estimates-down-yy?cid=sm-stocktwits-2-2463062-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2463062_TEASER
0 · Reply
Estimize
Estimize Apr. 30 at 8:00 PM
Wall St is expecting 1.47 EPS for $ASH Q3 [Reporting 07/29 AMC] http://www.estimize.com/intro/ash?chart=historical&metric_name=eps&utm_cont
0 · Reply
Bsheskey
Bsheskey Apr. 15 at 8:16 PM
$ASH Could Quickly Scale into GLP-1 API's if Pharma Tariffs take effect. $NVO or $LLY should target. ASAP
0 · Reply
JarvisFlow
JarvisFlow Apr. 9 at 5:30 PM
Wells Fargo updates rating for Ashland ( $ASH ) to Overweight, target set at 69 → 58.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 10:26 AM
$ASH Digging ASH's strategic pivot. Avoca sale looks smart. Life Sciences hit hard but Personal Care segment showing resilience. Watching how cost-cutting plays out. Cautiously optimistic on long-term potential. Might nibble on dip if market overreacts. compelling writeup: https://beyondspx.com/article/ashland-inc-ash-a-specialty-chemicals-powerhouse-navigating-challenges-with-strategic-precision
0 · Reply
IndulgeJackal
IndulgeJackal Mar. 27 at 1:52 PM
$ASH 🚨 BREAKING NEWS from Mainz Biomed 🚨 Mainz Biomed just enrolled the first patient in its eAArly DETECT 2 clinical study - a groundbreaking 2,000-patient trial designed to validate its next-gen colorectal cancer (CRC) test that could shift CRC screening to prevention! 🧬🔍 Key Highlights: ✅ Industry-leading mRNA biomarkers + AI-driven algorithm ✅ Detects advanced precancerous lesions (APL) with high precision ✅ Potential to prevent CRC by catching treatable polyps early ✅ Top-line results expected Q4 2025 ✅ Pivotal U.S. study (ReconAAsense) planned for 2026 “This marks a huge milestone in our mission to eliminate colorectal cancer and save lives,” said CEO Guido Baechler. 🌍💥
0 · Reply
JarvisFlow
JarvisFlow Mar. 27 at 1:04 PM
Wells Fargo has adjusted their stance on Ashland ( $ASH ), setting the rating to Overweight with a target price of 80 → 69.
0 · Reply
JarvisFlow
JarvisFlow Mar. 26 at 12:00 PM
JP Morgan updates rating for Ashland ( $ASH ) to Overweight, target set at 68 → 71.
0 · Reply
ajmrtxl
ajmrtxl Mar. 25 at 5:09 PM
$ASH's latest data on SqueezeFinder
0 · Reply
BigSqueezeComing
BigSqueezeComing Mar. 24 at 11:04 AM
$DMN $ASH $IMTE $WINT $MLGO continue from AH
0 · Reply
kshonstocks
kshonstocks Mar. 19 at 2:49 PM
chemicals act wrong, distribution in $ASH $WLK et al
0 · Reply
JarvisFlow
JarvisFlow Mar. 5 at 2:00 PM
Seaport Global has updated their rating for Ashland ( $ASH ) to Neutral.
0 · Reply
Jamesiam
Jamesiam Jan. 29 at 11:21 PM
$ASH anyone buying
5 · Reply
DonCorleone77
DonCorleone77 Jan. 28 at 10:06 PM
$ASH Ashland reports Q1 EPS 28c, consensus 18c Reports Q1 revenue $405M, consensus $427M. "Since announcing the sale agreement for our Avoca business, we are nearing the final stages of our portfolio optimization activities. The last stage will be to fully implement our $30 million cost reduction plan to offset the stranded costs and gross profit loss from the sale of the nutraceutical business," said Guillermo Novo, CEO. "Ashland continues to demonstrate strategic progress and operating discipline amid softer market conditions, generally consistent with the first-quarter update shared at our strategy day event in December. Organic sales volumes declined by one percent, primarily due to lower demand in Europe and inventory control actions by our pharmaceutical customers. This decline was mostly offset by improved sales volumes in Personal Care, Specialty Additives, and Intermediates. Pricing impacts moderated in the quarter, reflecting our team's disciplined approach to a stable raw material environment. Given the significant uncertainty surrounding trade policy under the incoming U.S. administration, we moved major annual maintenance turnarounds to the first quarter. This builds greater resilience to respond to potential trade and economic changes. While this action shifted planned expenses forward, it significantly enhanced our operational flexibility to navigate uncertain markets. With our Portfolio Optimization behind us, our top priority is to advance our strategy through execution discipline, globalizing four high-quality business lines and advancing the commercialization of our new technology platforms. In the near term, our focus remains on delivering and accelerating cost savings and enhancing productivity initiatives."
0 · Reply